Clinical trials · Raleigh–Durham, NC
Esophageal Adenocarcinoma clinical trials in Raleigh–Durham
We’re tracking 18 recruiting esophageal adenocarcinoma studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Cary, North CarolinaAges 40–75 - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Durham, North CarolinaAges 18–130 - NCT05563766RecruitingPhase 2
Itraconazole with standard treatment for esophageal cancer
This trial tests whether adding the antifungal drug itraconazole to the usual chemotherapy and radiation before surgery can improve the chance of no cancer cells remaining at surgery. It is for patients with esophageal or gastroesophageal junction cancer that can be surgically removed.
Durham, North CarolinaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Durham, North CarolinaAges 18 years+ - NCT07603375RecruitingPhase 2
Chemotherapy and radiation for esophageal adenocarcinoma
This trial tests a combination of chemotherapy drugs given together with radiation therapy, followed by additional chemotherapy, for newly diagnosed adenocarcinoma (a type of cancer) in the esophagus or where the esophagus meets the stomach. The goal is to shrink the tumor and improve survival.
Durham, North CarolinaAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Durham, North CarolinaAges 18 years+ - NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Durham, North CarolinaAges 18 years+ - NCT02427269Enrolling by invitation
Blood and tissue sample study for esophagus conditions
This study collects blood and biopsy tissue from people who are having an upper endoscopy at UNC for Barrett’s esophagus or esophageal cancer. The samples help researchers build a biorepository to study these conditions and support future research.
Chapel Hill, North CarolinaAges 18 years+ - NCT05677490RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced stomach or esophagus cancer
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
Chapel Hill, North CarolinaAges 18 years+ - NCT05530343Recruiting
Two ways to sample tissue during Barrett’s follow-up
This study compares two tissue-collection methods during an endoscopy for Barrett’s esophagus to see which one detects concerning changes better. Your results could help improve how doctors check Barrett’s over time.
Chapel Hill, North CarolinaAges 18–89 - NCT06687603Recruiting
Detecting Barrett's esophagus in people without heartburn
This study aims to screen for Barrett's esophagus in people who are getting a routine colonoscopy but do not have chronic heartburn. It uses a simple, non-invasive cell collection device (EsoCheck) to see if you might have Barrett's esophagus, which can increase the risk of esophageal cancer.
Chapel Hill, North CarolinaAges 50 years+ - NCT00288119Recruiting
Study genes in Barrett’s esophagus and esophageal cancer
This study looks at genetic (inherited) factors that may be linked to Barrett’s esophagus and esophageal cancer. It may help researchers understand why these conditions happen in some families and others do not.
Chapel Hill, North CarolinaAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Chapel Hill, North CarolinaAges 18 years+ - NCT06732388RecruitingPhase 2
Itraconazole with ablation to prevent esophageal cancer in Barrett's esophagus
This trial tests if adding the antifungal drug itraconazole to standard ablation therapy can help prevent esophageal cancer in people with high-risk Barrett's esophagus. You must have a confirmed diagnosis of Barrett's esophagus with low- or high-grade dysplasia or early-stage cancer, and be planning to have ablation treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT05753748Recruiting
Surveillance vs. endoscopic treatment for Barrett's esophagus with low-grade dysplasia
This study compares two approaches for people with Barrett's esophagus and low-grade dysplasia: regular surveillance (monitoring with endoscopies) versus endoscopic treatment to remove the abnormal cells. It aims to see which approach is better at preventing progression to more serious conditions.
Chapel Hill, North CarolinaAges 18–89 - NCT04939051RecruitingPhase 2
Obeticholic acid to prevent Barrett’s esophagus worsening
This Phase 2 trial tests whether obeticholic acid (a medicine) can help stop Barrett’s esophagus from getting worse. You must already be taking acid-suppressing medicine and have non-cancer Barrett’s changes, and the study checks safety and whether the lining improves or stays stable.
Chapel Hill, North CarolinaAges 18 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Chapel Hill, North CarolinaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Burlington, North CarolinaAges 18 years+
Hear when a new Esophageal Adenocarcinoma trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Esophageal Adenocarcinoma trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting esophageal adenocarcinoma studies listed above.
- University of North Carolina at Chapel Hill · 4 studies
- UNC Lineberger Comprehensive Cancer Center · 3 studies
- Research Site · 2 studies
- Cone Health Cancer Center at Alamance Regional
- Duke Cancer Center Durham
- Duke Cancer Institute
- Duke University Medical Center
- Durham VA Medical Center
What taking part in a esophageal adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting esophageal adenocarcinoma studies in North Carolina.
Common questions
- Are there esophageal adenocarcinoma clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 18 recruiting esophageal adenocarcinoma studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a esophageal adenocarcinoma study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a esophageal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New esophageal adenocarcinoma studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.